Genetic analysis in women with metastatic ovarian cancer during PARP inhibitor treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the genetic landscape of women with metastatic ovarian cancer who are receiving treatment with PARP inhibitors. It focuses on analyzing peripheral blood and bone marrow samples to identify potential dysplastic changes and abnormalities in hematopoietic lineages. The study aims to evaluate the impact of PARP inhibition on different cell populations and assess the risk of therapy-related acute myeloid leukemia and myelodysplasia. By utilizing advanced techniques such as multiparametric FACS analysis, the research seeks to enhance understanding of treatment effects on cancer progression.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Women with advanced ovarian cancer in complete or partial remission after surgery and eligible to oral PARP inhibitors as first line in association to chemotherapy or as maintenance therapy.

Exclusion Criteria:

* Presence of blood cell count abnormalities before PARP inhibitor treatment;
* Bone marrow infiltration by EOC cells.

Where it's running

• Istituto Europeo di Oncologia
  Milan, Italy Recruiting

Study contacts

• Principal investigator: Federica Gigli — Istituto Europeo di Oncologia
• Study coordinator: Federica Gigli
• Email: federica.gigli@ieo.it
• Phone: +390257489538

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Electronic mindfulness-based music therapy for patients receiving stem cell transplantation

  This trial tests an eHealth mindfulness-based music therapy to see if it improves quality of life and reduces symptoms for adults undergoing stem cell transplantation.

  Recruiting University of Miami · Miami, Florida · NCT07469592

• Orca-T after reduced-intensity or nonmyeloablative conditioning for adults with AML or MDS

  This trial will test whether Orca-T, a donor-derived stem cell and T-cell therapy, is safe and helps adults with acute myeloid leukemia or myelodysplastic syndrome who are receiving reduced-intensity or nonmyeloablative allogeneic stem cell transplants.

  Recruiting at 6 sites Phase 2 Orca Biosystems, Inc. · Los Angeles, California and 5 other locations · NCT07216443

• Registry for patients with myelodysplastic syndromes and therapy-related acute myeloid leukemia

  This study is collecting health information from adults with myelodysplastic syndromes and therapy-related acute myeloid leukemia to better understand these conditions and improve patient care.

  Recruiting Groupe Francophone des Myelodysplasies · Rouen · NCT06956755

• Bleximenib added to venetoclax and azacitidine for newly diagnosed NPM1- or KMT2A-mutated AML

  This trial will test whether adding bleximenib to venetoclax plus azacitidine helps people with newly diagnosed AML that has NPM1 or KMT2A mutations who cannot have intensive chemotherapy.

  Recruiting at 270 sites Phase 3 Janssen Research & Development, LLC · Birmingham, Alabama and 269 other locations · NCT06852222

• Combining Venetoclax with Intensive Therapy for Acute Myeloid Leukemia Patients

  This study is testing if adding a drug called Venetoclax to standard chemotherapy can help newly diagnosed acute myeloid leukemia patients who aren't responding well to their initial treatment.

  Recruiting Affiliated Hospital of Nantong University · Nantong, Jiangsu · NCT06643962

• Genetic factors affecting treatment response in acute myeloid leukemia

  This study is testing how certain genetic differences affect the side effects and success of a treatment for people newly diagnosed with acute myeloid leukemia who are receiving azacitidine and venetoclax.

  Recruiting at 2 sites Wake Forest University Health Sciences · Charlotte, North Carolina and 1 other locations · NCT06580106

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.